Spontaneous remission of iMCD-TAFRO: a case report

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Idiopathic multicentric Castleman disease (iMCD)- TAFRO is a severe hematologic disorder.
• It is characterized by life-threatening cytokine storms.
• Current treatment guidelines recommend siltuximab and high-dose steroids.

Observation:

• A rare case of iMCD-TAFRO presented with spontaneous remission.
• The patient's symptoms and laboratory results improved without specific etiological treatment.
• This occurred after the initial cytokine storm stabilized.

Findings:

• Spontaneous remission is a possible, albeit rare, outcome in iMCD-TAFRO.
• The patient achieved clinical and laboratory normalization without targeted therapy.
• This challenges the assumption of universal need for continuous treatment.

Implications:

• This case highlights the importance of reassessing treatment needs after initial stabilization.
• It suggests that not all iMCD-TAFRO patients require long-term aggressive therapy.
• Further research into the mechanisms of spontaneous remission could inform novel therapeutic strategies.